(Q44480091)

English

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

0 references

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Matthias Herz

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Don Johns

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jesus Reviriego

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Loren D Grossman

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Chantal Godin

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Santiago Duran

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Federico Hawkins

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Heather Lochnan

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Fernando Escobar-Jiménez

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Philip A Hardin

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Christopher S Konkoy

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Meng H Tan

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 April 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1074-1095

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Standards of medical care for patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980068-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80068-1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44480091&oldid=2025300294"